Open Actively Recruiting

Phase 3 Clinical Study of AK112 for NSCLC Patients


Brief Summary

A Randomized, Double-blind, Multi-center, Phase III Clinical Study of Ivonescimab (SMT112 or AK112) or Placebo Plus Pemetrexed and Carboplatin in Patients With EGFR-mutant Locally Advanced or Metastatic Non-squamous Non-small Cell Lung Cancer Who Have Progressed on or Following Growth Factor Receptor Tyrosine Kinase Inhibitor (EGFR-TKI) Treatment (HARMONi)

Primary Purpose
Study Type
Phase 3


Healthy Volunteers
Minimum Age
18 Years
Maximum Age

Inclusion Criteria:

  • Ability to understand and voluntarily sign a written informed consent form (ICF), which must be signed before the specified study procedures required for the study are performed.
  • Males or females aged ≥ 18 years at the time of signing informed consent.
  • Eastern Cooperative Oncology Group (ECOG) Performance Status (PS) 0 or 1.
  • Life expectancy ≥3 months;
  • Locally advanced (stage IIIB/IIIC) or metastatic (stage IV) non-squamous NSCLC confirmed by histology or cytology, inoperable and unable to receive radiotherapy and chemotherapy;
  • The tumor histology, cytology or hematology confirmed the presence of EGFR activating mutations before enrollment
  • Have previously received 3rd generation EGFR-TKI treatment and have progressed on or following
  • Subjects have at least one measurable non-brain tumor lesion per RECIST v1.1
  • Major organ function prior to treatment meets the following criteria
  • Patients of childbearing potential must agree to use effective contraceptive measures

Exclusion Criteria:

  • Histological or cytological pathology confirmed the presence of small cell carcinoma components, or the main component is squamous cell carcinoma
  • There are reports confirming the existence of other driver gene mutations with known drug treatments
  • Subjects who received any prior treatments targeting the mechanism of tumor immunity
  • The subject has received systemic anti-tumor therapy other than EGFR-TKI
  • Currently enrolled in any other clinical study
  • Received EGFR-TKI treatment, palliative local treatment, non-specific immunomodulatory treatment within 2 weeks prior to the first dose.
  • Tumor surrounds important blood vessels or has obvious necrosis, cavitation, or invades surrounding important organs and blood vessels.
  • Symptomatic central nervous system metastases
  • Active malignancies within the past 3 years, with the exception of tumors in this study and cured local tumors
  • Active autoimmune disease requiring systemic treatment within 2 years prior to the start of study treatment
  • There is a history of major diseases 1 year prior to the first dose.
  • .Medical history of gastrointestinal perforation or gastrointestinal fistula within 6 months prior to the first dose
  • Received chest radiation therapy prior to the first dose
  • Presence of clinically symptomatic pleural effusion, pericardial effusion, or ascites requiring frequent drainage.
  • Active or previously documented inflammatory bowel disease (e.g., Crohn's disease or ulcerative colitis).

Join this Trial

Contact our clinical trial navigators for opportunities that may be suitable for you
Study Stats
Protocol No.
Lung Cancer
Angela Lool
  • UCLA Alhambra
  • UCLA Irvine
  • UCLA Laguna Hills
  • UCLA Playa Marina
  • UCLA Porter Ranch
  • UCLA Santa Barbara
  • UCLA Santa Monica
  • UCLA Westwood
For Providers
For detailed technical eligibility, visit